[1] ORONSKY B, GUO X N, WANG X H, et al. Discovery of RRx-001, a myc and CD47 downregulating small molecule with tumor targeted cytotoxicity and healthy tissue cytoprotective properties in clinical development[J]. J Med Chem, 2021, 64(11):7261-7271. doi:  10.1021/acs.jmedchem.1c00599
[2] ORONSKY B, REID T R, LARSON C, et al. REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer[J]. Future Oncol, 2019, 15(30):3427-3433. doi:  10.2217/fon-2019-0317
[3] JURGENSEN K J, SKINNER W K J, ORONSKY B, et al. RRx-001 radioprotection: enhancement of survival and hematopoietic recovery in gamma-irradiated mice[J]. Front Pharmacol, 2021, 12:676396. doi:  10.3389/fphar.2021.676396
[4] MORGENSZTERN D, ROSE M, WAQAR S N, et al. RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer[J]. Br J Cancer, 2019, 121(3):211-217. doi:  10.1038/s41416-019-0504-8
[5] REID T R, ABROUK N, CAROEN S, et al. ROCKET: phase II randomized, active-controlled, multicenter trial to assess the safety and efficacy of RRx-001 + irinotecan vs. single-agent regorafenib in third/fourth line colorectal cancer[J]. Clin Colorectal Cancer, 2023, 22(1):92-99. doi:  10.1016/j.clcc.2022.11.003
[6] REID T, ORONSKY B, CAROEN S, et al. Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer(PRIMETIME)[J]. Front Immunol, 2023, 14:1104753. doi:  10.3389/fimmu.2023.1104753
[7] FINE H, REID T, CAROEN S, et al. A multicenter, phase 1, dose escalation clinical trial(G-FORCE-1)of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma[J]. Front Oncol, 2023, 13:1176448. doi:  10.3389/fonc.2023.1176448
[8] ORONSKY B, PAULMURUGAN R, FOYGEL K, et al. RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials[J]. Expert Opin Investig Drugs, 2017, 26(1):109-119. doi:  10.1080/13543784.2017.1268600
[9] JANI V P, ASARO R, ORONSKY B, et al. RRx-001 increases erythrocyte preferential adhesion to the tumor vasculature[J]. Int J Mol Sci, 2021, 22(9):4713. doi:  10.3390/ijms22094713
[10] ZHAO H J, NING S C, SCICINSKI J, et al. Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity[J]. Oncotarget, 2015, 6(41):43172-43181. doi:  10.18632/oncotarget.6526
[11] ORONSKY B, CABRALES P, CAROEN S, et al. RRx-001, a downregulator of the CD47- SIRPα checkpoint pathway, does not cause anemia or thrombocytopenia[J]. Expert Opin Drug Metab Toxicol, 2021, 17(4):355-357. doi:  10.1080/17425255.2021.1876025
[12] 李洪珍, 舒远杰, 刘世俊, 等. N-乙酰基-3, 3-二硝基氮杂环丁烷的合成[J]. 化学研究与应用, 2004, 16(3):393-395.
[13] 李洪珍, 舒远杰, 黄奕刚, 等. 3, 3-二硝基氮杂环丁烷和1, 1'-亚甲基-双(3, 3-二硝基-1-氮杂环丁烷)的合成研究[J]. 有机化学, 2004, 24(7):775-777.
[14] TANG W M, ZHANG Y M, YANG K L, et al. Discovery of novel 3, 11-bispeptide ester arenobufagin derivatives with potential in vivo antitumor activity and reduced cardiotoxicity[J]. Chem Biodivers, 2023, 20(2):e202200911. doi:  10.1002/cbdv.202200911
[15] ZHANG Y M, YANG K L, YE S, et al. Application of a fluorine strategy in the lead optimization of betulinic acid to the discovery of potent CD73 inhibitors[J]. Steroids, 2022, 188:109112. doi:  10.1016/j.steroids.2022.109112
[16] 罗川, 马建江, 缪震元, 等. 沙蟾毒精酯类衍生物的合成和抗肿瘤活性研究[J]. 药学实践杂志, 2021, 39(1):35-37,57.